By Associate Professor Suzanne Jean Hodgkinson

Journal articles

Tran GT; Bedi S; Rakesh P; Verma ND; Carter N; Robinson CM; Al-Atiyah R; Hall BM; Hodgkinson SJ, 2025, 'Autoantigen and IL-2 activated CD4+CD25+T regulatory cells are induced to express CD8 and are autoantigen specific in inhibiting experimental autoimmune encephalomyelitis', Journal of Neuroimmunology, 404, http://dx.doi.org/10.1016/j.jneuroim.2025.578611

Verma ND; Al-Atiyah R; Rakesh P; Lam AD; Chiu C; Tran GT; Hall BM; Hodgkinson SJ, 2025, 'Frequency and stability of populations of CD4+ and CD4+CD25+Foxp3+CD127lo Treg in healthy adults defined by cytometry using monoclonal antibodies to T cell associated molecules.', Cytometry B Clin Cytom, http://dx.doi.org/10.1002/cyto.b.22241

Toscano S; Spelman T; Ozakbas S; Alroughani R; Chisari CG; Lo Fermo S; Prat A; Girard M; Duquette P; Izquierdo G; Eichau S; Grammond P; Boz C; Kalincik T; Blanco Y; Buzzard K; Skibina O; Sa MJ; van der Walt A; Butzkueven H; Terzi M; Gerlach O; Grand'Maison F; Foschi M; Surcinelli A; Barnett M; Lugaresi A; Onofrj M; Yamout B; Khoury SJ; Prevost J; Lechner-Scott J; Maimone D; Amato MP; Spitaleri D; Van Pesch V; Macdonell R; Cartechini E; de Gans K; Slee M; Castillo-Triviño T; Soysal A; Sanchez-Menoyo JL; Laureys G; Van Hijfte L; McCombe P; Altintas A; Weinstock-Guttman B; Aguera-Morales E; Etemadifar M; Ramo-Tello C; John N; Turkoglu R; Hodgkinson S; Besora S; Van Wijmeersch B; Fernandez-Bolaños R; Patti F, 2025, 'First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis', Neurotherapeutics, 22, http://dx.doi.org/10.1016/j.neurot.2025.e00552

Li V; McKay FC; Tscharke DC; Smith C; Khanna R; Lechner-Scott J; Rawlinson WD; Lloyd AR; Taylor BV; Morahan JM; Steinman L; Giovannoni G; Bar-Or A; Levy M; Drosu N; Potter A; Caswell N; Smith L; Brady EC; Frost B; Hodgkinson S; Hardy TA; Broadley SA, 2025, 'Repurposing Licensed Drugs with Activity Against Epstein–Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach', CNS Drugs, 39, pp. 305 - 320, http://dx.doi.org/10.1007/s40263-024-01153-5

Campbell JA; Henson GJ; Ngwa VF; Ahmad H; Taylor BV; van der Mei I; Ramanathan S; Hardy TA; Shaw C; Garber J; Macdonell R; McCombe P; John N; Hodgkinson S; van der Walt A; Lechner-Scott J; Roos I; Kalincik T; Carroll WM; Fabis-Pedrini M; Kermode AG; Butzkueven H; Palmer AJ, 2025, 'Correction to: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications (PharmacoEconomics, (2025), 43, 2, (223-239), 10.1007/s40273-024-01417-4)', Pharmacoeconomics, 43, pp. 241, http://dx.doi.org/10.1007/s40273-024-01461-0

Campbell JA; Henson GJ; Ngwa VF; Ahmad H; Taylor BV; van der Mei I; Ramanathan S; Hardy TA; Shaw C; Garber J; Macdonell R; McCombe P; John N; Hodgkinson S; Walt AVD; Lechner-Scott J; Roos I; Kalincik T; Carroll WM; Fabis-Pedrini M; Kermode AG; Butzkueven H; Palmer AJ, 2025, 'Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications', Pharmacoeconomics, 43, pp. 223 - 239, http://dx.doi.org/10.1007/s40273-024-01417-4

Wiendl H; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Schmierer K; Sellebjerg F; Vermersch P; Jin H; Chudecka A; Kloetgen A; Lin D; Gardner L; De Stefano N, 2025, 'Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study', Frontiers in Immunology, 16, http://dx.doi.org/10.3389/fimmu.2025.1512189

Wiendl H; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Schmierer K; Sellebjerg F; Vermersch P; Jin H; Chudecka A; Kloetgen A; Lin D; Gardner L; De Stefano N, 2025, 'Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study (Frontiers in Immunology, (2025), 16, (1512189), 10.3389/fimmu.2025.1512189)', Frontiers in Immunology, 16, http://dx.doi.org/10.3389/fimmu.2025.1571978

Müller J; Sharmin S; Lorscheider J; Ozakbas S; Karabudak R; Horakova D; Weinstock-Guttman B; Shaygannejad V; Etemadifar M; Alroughani R; Patti F; Eichau S; Prat A; Lugaresi A; Tomassini V; Kermode AG; Amato MP; Turkoglu R; Altintas A; Buzzard K; Soysal A; Van Der Walt A; Butzkueven H; Blanco Y; Gerlach O; Khoury SJ; Barnett M; John N; Lechner-Scott J; Foschi M; Surcinelli A; Van Pesch V; Prevost J; Sa MJ; Maimone D; D'hooghe M; Hughes S; Hodgkinson S; Mcguigan C; Cartechini E; Taylor B; Spitaleri D; Slee M; Mccombe P; Yamout B; Benkert P; Kuhle J; Kappos L; Roos I; Kalincik T; Havrdova EK; Girard M; Duquette P; Fabis-Pedrini M; Carroll WM; Skibina O; Gouider R; Mrabet S; Ramo-Tello C; Solaro C; Habek M; Van Wijmeersch B; Ampapa R; Macdonell R; Oreja-Guevara C; De Gans K; Laureys G; Oh J; Garber J; Gray O; Agüera-Morales E; Sanchez-Menoyo JL; Castillo-Triviño T; Grigoriadis N; Petersen T; Hardy TA; Vucic S; Reddel S; Ramanathan S; Al-Asmi A; Simu M; Baghbanian SM; Poehlau D; Al-Harbi T; Rojas JI; Deri N; Lalive P; Cambron M; Csepany T; Shuey N; Willekens B; Shaw C; Decoo D; Massey J; Yaldizli Ö; Derfuss T; Granziera C, 2025, 'Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis', JAMA Neurology, http://dx.doi.org/10.1001/jamaneurol.2025.0495

De Stefano N; Vermersch P; Wiendl H; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Prat A; Leocani L; Schmierer K; Sellebjerg F; Lehn A; Smyk A; Nolting A; Koelbach R; Hodgkinson S, 2025, 'Efficacité à long terme de la Cladribine comprimé (CladT) sur 4 ans dans la sclérose en plaques récurrente (SEP R) : résultats de l’étude d’extension MAGNIFY-MS', Revue Neurologique, 181, pp. S145 - S145, http://dx.doi.org/10.1016/j.neurol.2025.01.282

Yeh WZ; Van Der Walt A; Skibina OG; Kalincik T; Alroughani R; Kermode AG; Fabis-Pedrini MJ; Carroll WM; Lechner-Scott J; Boz C; Ozakbas S; Buzzard K; Habek M; John NA; Prat A; Girard M; Duquette P; Baghbanian SM; Hodgkinson S; Van Pesch V; Laureys G; Willekens B; Prevost J; Foschi M; De Gans K; Horakova D; Havrdova EK; Karabudak R; Patti F; McCombe PA; Maimone D; Altintas A; Ampapa R; Spitaleri D; Gerlach OHH; Sa MJ; Hughes S; Gouider R; Mrabet S; MacDonell RA; Turkoglu R; Cartechini E; Al-Asmi A; Soysal A; Oh J; Muros-Le Rouzic E; Guye S; Pasquarelli N; Butzkueven H; Jokubaitis VG; Barnett M; Slee M; Van Hijfte L; Yamout B; Terzi M; Blanco Y; Grammond P; Izquierdo G; Besora S; Taylor B; Castillo-Triviño T; Sanchez-Menoyo JL; Lugaresi A; Amato MP; Hardy T; Decoo D; Fragoso Y; Iuliano G; Gray O; Saladino ML; Grand'Maison F; Sempere AP; Shaw C; Van Wijmeersch B; Csepany T; Solaro C; Alkhaboori J; Garber J; Dominguez JA; Piroska I; McGuigan C; Cauchi M; Skromne E; Treviño-Frenk I; Mason D; Sirbu CA; Etemadifar M; Nohara C; Cambron M; De Vecino MCA; Shalaby N; Field D; Aguera-Morales E; Khurana D; Matsumoto R; Shimizu F; Sinnige LGF; Cárdenas-Robledo S, 2024, 'Disease Activity in Pregnant and Postpartum Women with Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies', Neurology Neuroimmunology and Neuroinflammation, 11, http://dx.doi.org/10.1212/NXI.0000000000200328

Lal AP; Foong YC; Sanfilippo PG; Spelman T; Rath L; Levitz D; Fabis-Pedrini M; Foschi M; Habek M; Kalincik T; Roos I; Lechner-Scott J; John N; Soysal A; D’Amico E; Gouider R; Mrabet S; Gross-Paju K; Cárdenas-Robledo S; Moghadasi AN; Sa MJ; Gray O; Oh J; Reddel S; Ramanathan S; Al-Harbi T; Altintas A; Hardy TA; Ozakbas S; Alroughani R; Kermode AG; Surcinelli A; Laureys G; Eichau S; Prat A; Girard M; Duquette P; Hodgkinson S; Ramo-Tello C; Maimone D; McCombe P; Spitaleri D; Sanchez-Menoyo JL; Yetkin MF; Baghbanian SM; Karabudak R; Al-Asmi A; Jakob GB; Khoury SJ; Etemadifar M; van Pesch V; Buzzard K; Taylor B; Butzkueven H; Van der Walt A, 2024, 'A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic', Journal of Neurology, 271, pp. 5813 - 5824, http://dx.doi.org/10.1007/s00415-024-12518-7

Roos I; Sharmin S; Malpas C; Ozakbas S; Lechner-Scott J; Hodgkinson S; Alroughani R; Eichau Madueño S; Boz C; van der Walt A; Butzkueven H; Buzzard K; Skibina O; Foschi M; Grand’Maison F; John N; Grammond P; Terzi M; Prévost J; Barnett M; Laureys G; Van Hijfte L; Luis Sanchez-Menoyo J; Blanco Y; Oh J; McCombe P; Ramo Tello C; Soysal A; Prat A; Duquette P; Yamout BI; Khoury S; van Pesch V; Macdonell R; José Sá M; Slee M; Kuhle J; Maimone D; Spitaleri DLA; Willekens B; Asmi AA; Tallantyre E; Robertson NP; Coles A; L Brown JW; Kalincik T, 2024, 'Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis', Multiple Sclerosis Journal, 30, pp. 1163 - 1175, http://dx.doi.org/10.1177/13524585241267211

De Brouwer E; Becker T; Werthen-Brabants L; Dewulf P; Iliadis D; Dekeyser C; Laureys G; Van Wijmeersch B; Popescu V; Dhaene T; Deschrijver D; Waegeman W; De Baets B; Stock M; Horakova D; Patti F; Izquierdo G; Eichau S; Girard M; Prat A; Lugaresi A; Grammond P; Kalincik T; Alroughani R; Grand’Maison F; Skibina O; Terzi M; Lechner-Scott J; Gerlach O; Khoury SJ; Cartechini E; Van Pesch V; Sà MJ; Weinstock-Guttman B; Blanco Y; Ampapa R; Spitaleri D; Solaro C; Maimone D; Soysal A; Iuliano G; Gouider R; Castillo-Triviño T; Sánchez-Menoyo JL; van der Walt A; Oh J; Aguera-Morales E; Altintas A; Al-Asmi A; de Gans K; Fragoso Y; Csepany T; Hodgkinson S; Deri N; Al-Harbi T; Taylor B; Gray O; Lalive P; Rozsa C; McGuigan C; Kermode A; Sempere AP; Mihaela S; Simo M; Hardy T; Decoo D; Hughes S; Grigoriadis N; Sas A; Vella N; Moreau Y; Peeters L, 2024, 'Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study', Plos Digital Health, 3, http://dx.doi.org/10.1371/journal.pdig.0000533

Alysha D; Blair C; Thomas P; Pham T; Nguyen T; Cordato TR; Badge H; Chappelow N; Lin L; Edwards L; Thomas J; Hodgkinson S; Cappelen-Smith C; McDougall A; Cordato DJ; Parsons M, 2024, 'Comparative Prevalence of Cerebrovascular Disease in Vietnamese Communities in South-Western Sydney', Journal of Cardiovascular Development and Disease, 11, http://dx.doi.org/10.3390/jcdd11060164

Spelman T; Herring WL; Acosta C; Hyde R; Jokubaitis VG; Pucci E; Lugaresi A; Laureys G; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Ozakbas S; Alroughani R; Kalincik T; Duquette P; Girard M; Petersen T; Patti F; Csepany T; Granella F; Grand’Maison F; Ferraro D; Karabudak R; Jose Sa M; Trojano M; van Pesch V; Van Wijmeersch B; Cartechini E; McCombe P; Gerlach O; Spitaleri D; Rozsa C; Hodgkinson S; Bergamaschi R; Gouider R; Soysal A; Castillo-Triviño ; Prevost J; Garber J; de Gans K; Ampapa R; Simo M; Sanchez-Menoyo JL; Iuliano G; Sas A; van der Walt A; John N; Gray O; Hughes S; De Luca G; Onofrj M; Buzzard K; Skibina O; Terzi M; Slee M; Solaro C; Oreja-Guevara ; Ramo-Tello C; Fragoso Y; Shaygannejad V; Moore F; Rajda C; Aguera Morales E; Butzkueven H, 2024, 'Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom', Journal of Medical Economics, 27, pp. 109 - 125, http://dx.doi.org/10.1080/13696998.2023.2293379

Hardy TA; Aouad P; Barnett MH; Blum S; Broadley S; Carroll WM; Crimmins D; Griffiths D; Hodgkinson S; Lechner-Scott J; Lee A; Malhotra R; McCombe P; Parratt J; Plummer C; Van der Walt A; Martel K; Walker RA, 2024, 'Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme', Multiple Sclerosis Journal Experimental Translational and Clinical, 10, http://dx.doi.org/10.1177/20552173231226106

Siriratnam P; Sanfilippo P; van der Walt A; Sharmin S; Foong YC; Yeh WZ; Zhu C; Khoury SJ; Csepany T; Willekens B; Etemadifar M; Ozakbas S; Nytrova P; Altintas A; Al-Asmi A; Yamout B; Laureys G; Patti F; Simo M; Surcinelli A; Foschi M; McCombe PA; Alroughani R; Sánchez-Menoyo JL; Turkoglu R; Soysal A; Scott JL; Kalincik T; Butzkueven H; Jokubaitis V; Huda S; Monif M; Horakova D; Van Hijfte L; Boz C; Shalaby N; Grand'Maison F; Mario ; Habek ; Singhal B; Hodgkinson S; Buzzard K; Skibina O; Slee M; Alkhaboori J; Inshasi J; Lapointe E; Boggild M; Vucic S; Gray O; Khurana D; Amato MP; Cristiano E; Liu Y; Cartechini E; Al-Harbi T; Hardy T, 2024, 'Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study', Journal of Neurology Neurosurgery and Psychiatry, http://dx.doi.org/10.1136/jnnp-2024-334090

De Stefano N; Wiendl H; Barkhof F; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Schmierer K; Sellebjerg F; Vermersch P; Petit C; Gardner L; Montalban X, 2024, '160. Low Rate of Progression Independent of Relapse Activity (PIRA) in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets', Multiple Sclerosis and Related Disorders, 92, pp. 106121 - 106121, http://dx.doi.org/10.1016/j.msard.2024.106121

De Stefano N; Vermersch P; Wiendl H; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Prat A; Leocani L; Schmierer K; Sellebjerg F; Lehn A; Smyk A; Nolting A; Koelbach R; Hodgkinson S, 2024, '162. Long-term Effectiveness of Cladribine Tablets over 4 years in Relapsing Multiple Sclerosis: Results from the MAGNIFY-MS Extension Study', Multiple Sclerosis and Related Disorders, 92, pp. 106123 - 106123, http://dx.doi.org/10.1016/j.msard.2024.106123

Diouf I; Malpas CB; Sharmin S; Roos I; Horakova D; Kubala Havrdova E; Patti F; Shaygannejad V; Ozakbas S; Eichau S; Onofrj M; Lugaresi A; Alroughani R; Prat A; Duquette P; Terzi M; Boz C; Grand'maison F; Sola P; Ferraro D; Grammond P; Yamout B; Altintas A; Gerlach O; Lechner-Scott J; Bergamaschi R; Karabudak R; Iuliano G; McGuigan C; Cartechini E; Hughes S; Sa MJ; Solaro C; Kappos L; Hodgkinson S; Slee M; Granella F; De Gans K; McCombe PA; Ampapa R; Van Der Walt A; Butzkueven H; Sánchez-Menoyo JL; Vucic S; Laureys G; Sidhom Y; Gouider R; Castillo-Trivino T; Gray O; Aguera-Morales E; Al-Asmi A; Shaw C; Al-Harbi TM; Csepany T; Sempere AP; Treviño Frenk I; Stuart EA; Kalincik T, 2023, 'Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: Causal inference to emulate a multiarm randomised trial', Journal of Neurology Neurosurgery and Psychiatry, 94, pp. 1004 - 1011, http://dx.doi.org/10.1136/jnnp-2023-331499

Sharmin S; Roos I; Simpson-Yap S; Malpas C; Sánchez MM; Ozakbas S; Horakova D; Havrdova EK; Patti F; Alroughani R; Izquierdo G; Eichau S; Boz C; Zakaria M; Onofrj M; Lugaresi A; Weinstock-Guttman B; Prat A; Girard M; Duquette P; Terzi M; Amato MP; Karabudak R; Grand’Maison F; Khoury SJ; Grammond P; Lechner-Scott J; Buzzard K; Skibina O; van der Walt A; Butzkueven H; Turkoglu R; Altintas A; Maimone D; Kermode A; Shalaby N; Pesch VV; Butler E; Sidhom Y; Gouider R; Mrabet S; Gerlach O; Soysal A; Barnett M; Kuhle J; Hughes S; Sa MJ; Hodgkinson S; Oreja-Guevara C; Ampapa R; Petersen T; Ramo-Tello C; Spitaleri D; McCombe P; Taylor B; Prevost J; Foschi M; Slee M; McGuigan C; Laureys G; Hijfte LV; de Gans K; Solaro C; Oh J; Macdonell R; Aguera-Morales E; Singhal B; Gray O; Garber J; Wijmeersch BV; Simu M; Castillo-Triviño T; Sanchez-Menoyo JL; Khurana D; Al-Asmi A; Al-Harbi T; Deri N; Fragoso Y; Lalive PH; Sinnige LGF; Shaw C; Shuey N; Csepany T; Sempere AP; Moore F; Decoo D; Willekens B; Gobbi C; Massey J; Hardy T; Parratt J; Kalincik T, 2023, 'The risk of secondary progressive multiple sclerosis is geographically determined but modifiable', Brain, 146, pp. 4633 - 4644, http://dx.doi.org/10.1093/brain/awad218

Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Der Walt AV; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Morgado YB; Spitaleri DLA; Pesch VV; Horakova D; Ampapa R; Patti F; MacDonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H, 2023, 'A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry', Neurodegenerative Disease Management, 13, pp. 215 - 221, http://dx.doi.org/10.2217/nmt-2023-0005

Kalincik T; Sharmin S; Roos I; Freedman MS; Atkins H; Burman J; Massey J; Sutton I; Withers B; MacDonell R; Grigg A; Torkildsen Ø; Bo L; Lehmann AK; Havrdova EK; Krasulova E; Trněný M; Kozak T; Van Der Walt A; Butzkueven H; McCombe P; Skibina O; Lechner-Scott J; Willekens B; Cartechini E; Ozakbas S; Alroughani R; Kuhle J; Patti F; Duquette P; Lugaresi A; Khoury SJ; Slee M; Turkoglu R; Hodgkinson S; John N; Maimone D; Sa MJ; Van Pesch V; Gerlach O; Laureys G; Van Hijfte L; Karabudak R; Spitaleri D; Csepany T; Gouider R; Castillo-Triviño T; Taylor B; Sharrack B; Snowden JA; Mrabet S; Garber J; Sanchez-Menoyo JL; Aguera-Morales E; Blanco Y; Al-Asmi A; Weinstock-Guttman B; Fragoso Y; De Gans K; Kermode A, 2023, 'Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis', JAMA Neurology, 80, pp. 702 - 713, http://dx.doi.org/10.1001/jamaneurol.2023.1184

Zhu C; Kalincik T; Horakova D; Zhou Z; Buzzard K; Skibina O; Alroughani R; Izquierdo G; Eichau S; Kuhle J; Patti F; Grand'maison F; Hodgkinson S; Grammond P; Lechner-Scott J; Butler E; Prat A; Girard M; Duquette P; MacDonell RAL; Weinstock-Guttman B; Ozakbas S; Slee M; Sa MJ; Van Pesch V; Barnett M; Van Wijmeersch B; Gerlach O; Prevost J; Terzi M; Boz C; Laureys G; Van Hijfte L; Kermode AG; Garber J; Yamout B; Khoury SJ; Merlo D; Monif M; Jokubaitis V; Van Der Walt A; Butzkueven H, 2023, 'Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation', JAMA Neurology, 80, pp. 739 - 748, http://dx.doi.org/10.1001/jamaneurol.2023.1542

Daruwalla C; Shaygannejad V; Ozakbas S; Havrdova EK; Horakova D; Alroughani R; Boz C; Patti F; Onofrj M; Lugaresi A; Eichau S; Girard M; Prat A; Duquette P; Yamout B; Khoury SJ; Sajedi SA; Turkoglu R; Altintas A; Skibina O; Buzzard K; Grammond P; Karabudak R; van der Walt A; Butzkueven H; Maimone D; Lechner-Scott J; Soysal A; John N; Prevost J; Spitaleri D; Ramo-Tello C; Gerlach O; Iuliano G; Foschi M; Ampapa R; van Pesch V; Barnett M; Shalaby N; D’hooghe M; Kuhle J; Sa MJ; Fabis-Pedrini M; Kermode A; Mrabet S; Gouider R; Hodgkinson S; Laureys G; Van Hijfte L; Macdonell R; Oreja-Guevara C; Cristiano E; McCombe P; Sanchez-Menoyo JL; Singhal B; Blanco Y; Hughes S; Garber J; Solaro C; McGuigan C; Taylor B; de Gans K; Habek M; Al-Asmi A; Mihaela S; Castillo Triviño T; Al-Harbi T; Rojas JI; Gray O; Khurana D; Van Wijmeersch B; Grigoriadis N; Inshasi J; Oh J; Aguera-Morales E; Fragoso Y; Moore F; Shaw C; Baghbanian SM; Shuey N; Willekens B; Hardy TA; Decoo D; sempere AP; Field D; Wynford-Thomas R; Cunniffe NG; Roos I; Malpas CB; Coles AJ; Kalincik T; Brown JWL, 2023, 'Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis', Multiple Sclerosis Journal, 29, pp. 875 - 883, http://dx.doi.org/10.1177/13524585231151951

Diouf I; Malpas CB; Sharmin S; Roos I; Horakova D; Havrdova EK; Patti F; Shaygannejad V; Ozakbas S; Izquierdo G; Eichau S; Onofrj M; Lugaresi A; Alroughani R; Prat A; Girard M; Duquette P; Terzi M; Boz C; Grand'Maison F; Hamdy S; Sola P; Ferraro D; Grammond P; Turkoglu R; Buzzard K; Skibina O; Yamout B; Altintas A; Gerlach O; van Pesch V; Blanco Y; Maimone D; Lechner-Scott J; Bergamaschi R; Karabudak R; Iuliano G; McGuigan C; Cartechini E; Barnett M; Hughes S; Sa MJ; Solaro C; Kappos L; Ramo-Tello C; Cristiano E; Hodgkinson S; Spitaleri D; Soysal A; Petersen T; Slee M; Butler E; Granella F; de Gans K; McCombe P; Ampapa R; Van Wijmeersch B; van der Walt A; Butzkueven H; Prevost J; Sinnige LGF; Sanchez-Menoyo JL; Vucic S; Laureys G; Van Hijfte L; Khurana D; Macdonell R; Gouider R; Castillo-Triviño T; Gray O; Aguera-Morales E; Al-Asmi A; Shaw C; Deri N; Al-Harbi T; Fragoso Y; Csepany T; Perez Sempere A; Trevino-Frenk I; Schepel J; Moore F; Kalincik T, 2023, 'Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis', European Journal of Neurology, 30, pp. 1014 - 1024, http://dx.doi.org/10.1111/ene.15706

Roos I; Diouf I; Sharmin S; Horakova D; Havrdova EK; Patti F; Shaygannejad V; Ozakbas S; Izquierdo G; Eichau S; Onofrj M; Lugaresi A; Alroughani R; Prat A; Girard M; Duquette P; Terzi M; Boz C; Grand’Maison F; Sola P; Ferraro D; Grammond P; Turkoglu R; Buzzard K; Skibina O; Yamou B; Altintas A; Gerlach O; van Pesch V; Blanco Y; Maimone D; Lechner-Scott J; Bergamaschi R; Karabudak R; McGuigan C; Cartechini E; Barnett M; Hughes S; Sa MJ; Solaro C; Ramo-Tello C; Hodgkinson S; Spitaleri D; Soysal A; Petersen T; Granella F; de Gans K; McCombe P; Ampapa R; Van Wijmeersch B; van der Walt A; Butzkueven H; Prevost J; Sanchez-Menoyo JL; Laureys G; Gouider R; Castillo-Triviño T; Gray O; Aguera-Morales E; Al-Asmi A; Shaw C; Deri N; Al-Harbi T; Fragoso Y; Csepany T; Sempere AP; Trevino-Frenk I; Schepel J; Moore F; Malpas C; Kalincik T, 2023, 'Comparative effectiveness in multiple sclerosis: A methodological comparison', Multiple Sclerosis Journal, 29, pp. 326 - 332, http://dx.doi.org/10.1177/13524585231151394

Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Van Der Walt A; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Blanco Morgado Y; Spitaleri DLA; van Pesch V; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H, 2023, 'Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry', Multiple Sclerosis Journal, 29, pp. 221 - 235, http://dx.doi.org/10.1177/13524585221137502

Wiendl H; Schmierer K; Hodgkinson S; Derfuss T; Chan A; Sellebjerg F; Achiron A; Montalban X; Prat A; De Stefano N; Barkhof F; Leocani L; Vermersch P; Chudecka A; Mwape C; Holmberg KH; Boschert U; Roy S, 2023, 'Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy', Neurology Neuroimmunology and Neuroinflammation, 10, http://dx.doi.org/10.1212/NXI.0000000000200048

Oreja-Guevara C; Brownlee W; Celius EG; Centonze D; Giovannoni G; Hodgkinson S; Kleinschnitz C; Havrdova EK; Magyari M; Selchen D; Vermersch P; Wiendl H; Van Wijmeersch B; Salloukh H; Yamout B, 2023, 'Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence', Multiple Sclerosis and Related Disorders, 69, http://dx.doi.org/10.1016/j.msard.2022.104459

Zhong M; van der Walt A; Monif M; Hodgkinson S; Eichau S; Kalincik T; Lechner-Scott J; Buzzard K; Skibina O; Van Pesch V; Butler E; Prevost J; Girard M; Oh J; Butzkueven H; Jokubaitis V, 2023, 'Prediction of relapse activity when switching to cladribine for multiple sclerosis', Multiple Sclerosis Journal, 29, pp. 119 - 129, http://dx.doi.org/10.1177/13524585221111677

De Stefano N; Achiron A; Barkhof F; Chan A; Derfuss T; Hodgkinson S; Leocani L; Montalban X; Prat A; Schmierer K; Sellebjerg F; Vermersch P; Wiendl H; Keller B; Smyk A; Gardner L, 2023, 'Early onset of Action and Sustained Efficacy of MRI Outcomes during Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-Year MAGNIFY-MS Study', Multiple Sclerosis and Related Disorders, 71, pp. 104322 - 104322, http://dx.doi.org/10.1016/j.msard.2022.104322

Oreja-Guevara C; Brownlee W; Celius EG; Centonze D; Giovannoni G; Hodgkinson S; Kleinschnitz C; Havrdova EK; Magyari M; Selchen D; Vermersch P; Wiendl H; Van Wijmeersch B; Salloukh H; Yamout B, 2023, 'Expert Opinion on Long-Term Use of Cladribine Tablets for Multiple Sclerosis: Systematic Literature Review of Real-World Evidence', Multiple Sclerosis and Related Disorders, 71, pp. 104362 - 104362, http://dx.doi.org/10.1016/j.msard.2022.104362

Hodgkinson S; Derfuss T; Sellebjerg F; Vermersch P; Barkhof F; Schmierer K; De Stefano N; Achiron A; Leocani L; Chan A; Montalban X; Prat A; Kloetgen A; Jin H; Gardner L; Jarvinen E; Wiendl H, 2023, 'Investigation of Changes in Lymphocyte Subset Counts and their Relationship with MRI Outcomes in the Magnify-MS Study', Multiple Sclerosis and Related Disorders, 80, pp. 105237 - 105237, http://dx.doi.org/10.1016/j.msard.2023.105237

Cordato D; Blair C; Thomas P; Firtko A; Miller M; Edwards LS; Thomas J; Balabanski AH; Dos Santos A; Lin L; Hodgkinson S; Cappelen-Smith C; Beran RG; McDougall A; Parsons M, 2022, 'Cerebrovascular Disease Profiles of Culturally and Linguistically Diverse Communities in South Western Sydney and New South Wales', Cerebrovascular Diseases, 51, pp. 744 - 754, http://dx.doi.org/10.1159/000524242

Cheung J; Zahorowska B; Suranyi M; Wong JKW; Diep J; Spicer ST; Verma ND; Hodgkinson SJ; Hall BM, 2022, 'CD4+CD25+ T regulatory cells in renal transplantation', Frontiers in Immunology, 13, http://dx.doi.org/10.3389/fimmu.2022.1017683

Roos I; Malpas C; Leray E; Casey R; Horakova D; Havrdova EK; Debouverie M; Patti F; De Seze J; Izquierdo G; Eichau S; Edan G; Prat A; Girard M; Ozakbas S; Grammond P; Zephir H; Ciron J; Maillart E; Moreau T; Amato MP; Labauge P; Alroughani R; Buzzard K; Skibina O; Terzi M; Laplaud DA; Berger E; Grand'maison F; Lebrun-Frenay C; Cartechini E; Boz C; Lechner-Scott J; Clavelou P; Stankoff B; Prevost J; Kappos L; Pelletier J; Shaygannejad V; Yamout BI; Khoury SJ; Gerlach O; Spitaleri DLA; Van Pesch V; Gout O; Turkoglu R; Heinzlef O; Thouvenot E; McCombe PA; Soysal A; Bourre B; Slee M; Castillo-Trivino T; Bakchine S; Ampapa R; Butler EG; Wahab A; MacDonell RA; Aguera-Morales E; Cabre P; Ben NH; Van Der Walt A; Laureys G; Van Hijfte L; Ramo-Tello CM; Maubeuge N; Hodgkinson S; Sánchez-Menoyo JL; Barnett MH; Labeyrie C; Vucic S; Sidhom Y; Gouider R; Csepany T; Sotoca J; De Gans K; Al-Asmi A; Fragoso YD; Vukusic S; Butzkueven H; Kalincik T, 2022, 'Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis', Neurology, 99, pp. E1926 - E1944, http://dx.doi.org/10.1212/WNL.0000000000201029

Zhu C; Zhou Z; Roos I; Merlo D; Kalincik T; Ozakbas S; Skibina O; Kuhle J; Hodgkinson S; Boz C; Alroughani R; Lechner-Scott J; Barnett M; Izquierdo G; Prat A; Horakova D; Kubala Havrdova E; MacDonell R; Patti F; Khoury SJ; Slee M; Karabudak R; Onofrj M; Van Pesch V; Prevost J; Monif M; Jokubaitis V; Van Der Walt A; Butzkueven H, 2022, 'Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis', Journal of Neurology Neurosurgery and Psychiatry, 93, pp. 1330 - 1337, http://dx.doi.org/10.1136/jnnp-2022-330104

Sharmin S; Bovis F; Malpas C; Horakova D; Havrdova E; Izquierdo G; Eichau S; Trojano M; Prat A; Girard M; Duquette P; Onofrj M; Lugaresi A; Grand'Maison F; Grammond P; Sola P; Ferraro D; Terzi M; Gerlach O; Alroughani R; Boz C; Shaygannejad V; van Pesch V; Cartechini E; Kappos L; Lechner-Scott J; Bergamaschi R; Turkoglu R; Solaro C; Iuliano G; Granella F; Van Wijmeersch B; Spitaleri D; Slee M; McCombe P; Prevost J; Ampapa R; Ozakbas S; Sanchez-Menoyo J; Soysal A; Vucic S; Petersen T; de Gans K; Butler E; Hodgkinson S; Sidhom Y; Gouider R; Cristiano E; Castillo-Triviño T; Saladino M; Barnett M; Moore F; Rozsa C; Yamout B; Skibina O; van der Walt A; Buzzard K; Gray O; Hughes S; Sempere AP; Singhal B; Fragoso Y; Shaw C; Kermode A; Taylor B; Simo M; Shuey N; Al-Harbi T; Macdonell R; Dominguez JA; Csepany T; Sirbu C; Sormani MP; Butzkueven H; Kalincik T, 2022, 'Confirmed disability progression as a marker of permanent disability in multiple sclerosis', European Journal of Neurology, 29, pp. 2321 - 2334, http://dx.doi.org/10.1111/ene.15406

De Stefano N; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Schmierer K; Sellebjerg F; Vermersch P; Wiendl H; Keller B; Roy S, 2022, 'Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS', Neurology Neuroimmunology and Neuroinflammation, 9, pp. E1187, http://dx.doi.org/10.1212/NXI.0000000000001187

Vitkova M; Diouf I; Malpas C; Horakova D; Kubala Havrdova E; Patti F; Ozakbas S; Izquierdo G; Eichau S; Shaygannejad V; Onofrj M; Lugaresi A; Alroughani R; Prat A; Larochelle C; Girard M; Duquette P; Terzi M; Boz C; Grand'maison F; Sola P; Ferraro D; Grammond P; Butzkueven H; Buzzard K; Skibina O; Yamout BI; Karabudak R; Gerlach O; Lechner-Scott J; Maimone D; Bergamaschi R; Van Pesch V; Iuliano G; Cartechini E; José Sà M; Ampapa R; Barnett M; Hughes SE; Ramo-Tello CM; Hodgkinson S; Spitaleri DLA; Petersen T; Butler EG; Slee M; McGuigan C; McCombe PA; Granella F; Cristiano E; Prevost J; Taylor BV; Sãnchez-Menoyo JL; Laureys G; Van Hijfte L; Vucic S; MacDonell RA; Gray O; Olascoaga J; Deri N; Fragoso YD; Shaw C; Kalincik T, 2022, 'Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study', Neurology, 98, pp. E2401 - E2412, http://dx.doi.org/10.1212/WNL.0000000000200545

Butzkueven H; Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Van Der Walt A; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Morgado YB; Spitaleri DLA; Van Pesch V; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong S, 2022, 'Real-world Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry (P12-4.003)', Neurology, 98, http://dx.doi.org/10.1212/wnl.98.18_supplement.1373

Zhong M; van der Walt A; Stankovich J; Kalincik T; Buzzard K; Skibina O; Boz C; Hodgkinson S; Slee M; Lechner-Scott J; Macdonell R; Prevost J; Kuhle J; Laureys G; Van Hijfte L; Alroughani R; Kermode AG; Butler E; Barnett M; Eichau S; van Pesch V; Grammond P; McCombe P; Karabudak R; Duquette P; Girard M; Taylor B; Yeh W; Monif M; Gresle M; Butzkueven H; Jokubaitis VG, 2022, 'Prediction of multiple sclerosis outcomes when switching to ocrelizumab', Multiple Sclerosis Journal, 28, pp. 958 - 969, http://dx.doi.org/10.1177/13524585211049986

Hall BM; Verma ND; Tran GT; Hodgkinson SJ, 2022, 'Transplant Tolerance, Not Only Clonal Deletion', Frontiers in Immunology, 13, pp. 810798, http://dx.doi.org/10.3389/fimmu.2022.810798

Malpas CB; Roos I; Sharmin S; Buzzard K; Skibina O; Butzkueven H; Kappos L; Patti F; Alroughani R; Horakova D; Havrdova EK; Izquierdo G; Eichau S; Hodgkinson S; Grammond P; Lechner-Scott J; Kalincik T, 2022, 'Multiple Sclerosis Relapses Following Cessation of Fingolimod', Clinical Drug Investigation, 42, pp. 355 - 364, http://dx.doi.org/10.1007/s40261-022-01129-7

Bukhari W; Khalilidehkordi E; Mason DF; Barnett MH; Taylor BV; Fabis-Pedrini M; Kermode AG; Subramanian S; Waters P; Broadley SA; Broadley SA; Abernethy D; Bhuta S; Blum S; Boggild M; Boundy K; Brew BJ; Brilot F; Brownlee WJ; Bundell CS; Butzkueven H; Carroll WM; Chen C; Clarke L; Coulthard A; Dale RC; Das C; Dear K; Fulcher D; Gillis D; Hawke S; Heard R; Henderson APD; Heshmat S; Hodgkinson S; Jimenez Sanchez S; Kilpatrick TJ; King J; Kneebone C; Kornberg AJ; Lechner-Scott J; Lin MW; Lynch C; Macdonell RAL; Marriott MP; McCombe PA; O’Gorman C; Parratt JDE; Pender MP; Pereira J; Pollard JD; Prain KM; Ramanathan S; Reddell SW; Shaw C; Silvestrini RA; Slee M; Spies J; Stankovich J; Sutton I; Vincent A; Vucic S; Walsh M; Willoughby E; Wong RC; Woodhall M; Yiu EM, 2022, 'NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand', Journal of Neurology, 269, pp. 836 - 845, http://dx.doi.org/10.1007/s00415-021-10665-9

Clarke L; Bukhari W; O'Gorman CM; Khalilidehkordi E; Arnett S; Woodhall M; Prain KM; Parratt JDE; Barnett MH; Marriott MP; McCombe PA; Sutton I; Boggild M; Brownlee W; Carroll WM; Hodgkinson S; Macdonell RAL; Mason DF; Pereira J; Slee M; Das C; Henderson APD; Kermode AG; Lechner-Scott J; Waters P; Sun J; Broadley SA, 2022, 'Response to treatment in NMOSD: the Australasian experience', Multiple Sclerosis and Related Disorders, 58, http://dx.doi.org/10.1016/j.msard.2021.103408

Maltby VE; Lea RA; Monif M; Fabis-Pedrini MJ; Buzzard K; Kalincik T; Kermode AG; Taylor B; Hodgkinson S; McCombe P; Osborne M; Butzkueven H; Barnett M; Lechner-Scott J, 2022, 'Cladribine: a multicentre, LOng-term efficacy and Biomarker Australian Study (CLOBAS)', MULTIPLE SCLEROSIS JOURNAL, 28, pp. 26 - 26

Diouf I; Malpas CB; Sharmin S; Skibina O; Buzzard K; Lechner-Scott J; Barnett M; Hodgkinson S; Slee M; Butler E; McCombe P; van der Walt A; Butzkueven H; Vucic S; Macdonell R; Shaw C; Kalincik T, 2022, 'Variability of the response to immunotherapy among sub-groups of patients with multiple sclerosis', MULTIPLE SCLEROSIS JOURNAL, 28, pp. 7 - 7

Back to profile page